Adderall vs Strattera: Stimulant or Non-Stimulant for ADHD?

In the Adderall vs Strattera matchup, Adderall is a fast-acting, controlled stimulant that works within hours, while Strattera (atomoxetine) is a non-controlled, non-stimulant that builds up over several weeks and is often chosen when misuse risk, anxiety, tics, or stimulant side effects are a concern.

Neither one is “better” for everyone. They work in different ways, carry different warnings, and suit different people. The quick table below lays out the basics, and the rest of the page scores them head to head so you can walk into your next appointment with sharper questions.

At a glance	Drug class	DEA schedule	Onset	How often dosed	Generic name
Adderall	Central nervous system stimulant (amphetamine)	Schedule II controlled substance	Same day, usually within about an hour	IR: 1 to 3 times a day; XR: once a day	Mixed amphetamine salts (dextroamphetamine/amphetamine)
Strattera	Selective norepinephrine reuptake inhibitor (non-stimulant)	Not a controlled substance	Gradual; some change in week 1, fuller benefit over about a month or longer	Once a day in the morning, or split into morning and late afternoon/early evening	Atomoxetine

Adderall vs Strattera basics, based on the FDA-approved labels and MedlinePlus.

Both medicines need a prescription. Which one fits, what dose to use, and whether to switch are calls for the prescriber who knows your full history. What follows is background to help that conversation, not a substitute for it.

Adderall vs Strattera: Hours vs weeks

If you remember only one difference, make it this one. Adderall releases and blocks the reuptake of dopamine and norepinephrine, so its effect shows up on the first day. Many people notice sharper focus within an hour of an immediate-release tablet. Our post on how long Adderall takes to start working covers that timing in more detail.

Atomoxetine acts more quietly. It blocks the reuptake of norepinephrine, and the brain adjusts to that change over time. According to MedlinePlus guidance on atomoxetine, some people see a little improvement in the first week, but it may take up to a month to feel the full benefit. Some research in adults suggests response can keep growing past that first month.

That slow build has real-life effects. A student starting Strattera in late August may not see a clear difference until the school term is well underway. A parent who expects a “switch flipped” result, the way a stimulant can feel, may decide too early that the drug isn’t working. Knowing the timeline up front helps everyone stay patient and track progress fairly.

How long does Strattera take to work? A week-by-week picture

Everyone’s course is different, but the label’s dosing schedule and patient guidance point to a general pattern. Use this as a rough map, not a promise.

Time on Strattera	What often happens	What to watch and note
Week 1	Treatment starts at a lower dose. Little change in focus yet for most people.	Upset stomach, nausea, lower appetite, sleepiness or tiredness. Taking it with food may help the stomach; ask your prescriber.
Weeks 2 to 3	The prescriber may raise the dose toward a target level (the label allows an increase after at least 3 days). Early hints of calmer, steadier days may appear.	Mood changes, irritability, or any new dark thoughts, especially in children and teens. Report these right away.
Week 4	Around the point MedlinePlus says full benefit may begin to show.	Compare school or work reports with before treatment. Bring notes to a follow-up visit.
Weeks 5 to 8	Effect may keep building. Stomach side effects often ease.	Blood pressure and pulse checks, weight in kids, sleep quality.
Weeks 8 to 12 and beyond	A fair point to judge whether the medicine is helping enough.	Decide with the prescriber whether to continue, adjust, or try something else.

A general expectation guide for starting Strattera. Timing varies; CYP2D6 poor metabolizers may follow a slower dose schedule.

Tip for tracking: Keep a simple weekly log with two or three ratings, such as “finished tasks,” “patience,” and “sleep.” Small trends are easier to spot on paper than from memory, and they give your prescriber real data.

The 8-round scorecard

Here the Adderall vs Strattera comparison goes round by round. A “win” doesn’t mean one drug is safer or stronger for you. It means one tends to have the edge on that single feature, based on label data and how each drug works.

Round 1: Speed and strength on core symptoms

Stimulants such as Adderall are usually considered first-line for many people with ADHD because they act fast and tend to produce a larger average drop in inattention and hyperactivity. You can tell within days, even hours, whether a dose is helping.

Atomoxetine has proven benefit in controlled trials and a maintenance study in children, where those who stayed on it went longer before symptoms returned than those switched to placebo. Still, its average effect is generally smaller than a stimulant’s, and it takes longer to show. One upside: because it is in the body all day, it can smooth out the early morning and evening hours that a short stimulant may miss.

Round verdict: Adderall, for speed and average strength; Strattera earns credit for steady all-day coverage.

Round 2: Misuse, diversion, and is Strattera a controlled substance?

Adderall is a Schedule II controlled substance. Its label carries a boxed warning about abuse, misuse, and addiction, including the risk of overdose and death. Pills can also be shared or sold, which is why pharmacies track fills through a prescription drug monitoring program (PDMP) and refills have strict rules. Those same rules are why an Adderall refill can’t simply be phoned in.

Strattera is not a controlled substance. The Strattera prescribing information on DailyMed reports that it did not show stimulant or euphoric effects in abuse-potential testing. That makes it far less attractive for misuse, though any prescription can still cause harm if someone else takes it.

If you’re worried about a family member, the post on signs of Adderall misuse lists what to look for.

Round verdict: Strattera, clearly.

Round 3: Sleep

Trouble falling asleep is one of the most common stimulant complaints, and a late Adderall dose makes it worse. That is why the immediate-release label advises taking the first dose on waking and spacing the rest 4 to 6 hours apart, and why afternoon doses are often avoided.

Strattera’s sleep profile is mixed. In children, sleepiness and fatigue showed up more often than with placebo. In adults, insomnia appeared in about 15% of people on the drug compared with 8% on placebo. Some people feel drowsy; others sleep lightly. Switching the dose to evening is something a prescriber may consider if daytime sleepiness is a problem. Ongoing low energy has many causes, and why you might feel more tired than usual walks through the common ones.

Round verdict: Slight edge to Strattera, mainly because it lacks the late-day stimulant jolt.

Round 4: Appetite and weight

Both drugs can blunt hunger. Adderall’s appetite loss often peaks around lunchtime and fades by evening, which is why some families plan a big breakfast and a late snack. Its label calls for tracking height and weight in children because growth slowing has been seen with stimulants.

With Strattera, decreased appetite was reported in about 16% of children and adults in pooled trials. Nausea is especially common in adults (about 26% vs 6% on placebo), and children reported more stomach pain and vomiting. In short-term studies, kids on atomoxetine lost a small amount of weight on average while those on placebo gained. Longer-term data in the label suggest weight gain lagged early and then caught up by about three years.

Round verdict: A draw. Both suppress appetite; Strattera adds more stomach upset early on.

Round 5: Heart rate and blood pressure

Here the two are more alike than many people expect. Stimulants raise average blood pressure and pulse by a modest amount. Atomoxetine, because it boosts norepinephrine, does the same. The Strattera label notes that a minority of patients, roughly 5% to 10% in trials, had larger jumps in heart rate or blood pressure.

Both labels urge a heart history and exam before starting and say these drugs generally should not be used in people with serious structural heart problems, cardiomyopathy, or serious rhythm problems. Strattera also lists pheochromocytoma (a rare adrenal tumor) as a reason not to use it. Expect pulse and pressure checks at follow-ups with either drug.

Round verdict: Tie. Neither is heart-neutral.

Round 6: Mood and Strattera’s suicidality warning

This round matters most for parents. Strattera carries a boxed warning: children and teens taking it need close watching for suicidal thoughts and behavior, worsening symptoms, or unusual changes in behavior. In a pooled look at 12 pediatric trials with more than 2,200 young patients, suicidal thoughts were reported in about 0.4% of those on atomoxetine (5 of 1,357) and in none on placebo. No suicides occurred, and every reported case was in a child aged 6 to 12 during the first month.

The label also flags new aggression or hostility and asks prescribers to screen for bipolar disorder before starting, since mania or psychotic symptoms can occur. Adderall has its own mood risks: irritability, anxiety, and, rarely, psychotic or manic symptoms, plus a low “crash” mood as a dose wears off. Normal ups and downs are different from a worrying shift; this guide to what everyday mood swings can mean helps tell them apart.

Warning signs to report the same day: talk of death or self-harm, new withdrawal from friends, sudden agitation or panic, acting on dangerous impulses, or a big, unexplained change in behavior. If a child or adult is in immediate danger, call 911. For crisis support, call or text 988.

Round verdict: Adderall, narrowly, since it lacks a suicidality boxed warning; both still require mood monitoring.

Round 7: Liver injury, priapism, and other rare Strattera side effects

Strattera side effects include a few rare but serious ones. Severe liver injury has been reported after approval, in rare cases leading to liver failure and transplant. The label says to stop the drug and not restart it if jaundice or lab signs of liver injury appear. Watch for dark urine, yellow skin or eyes, itching, right-side belly pain, or unexplained flu-like symptoms.

Priapism, a painful erection lasting more than four hours, has also been reported rarely, including in children, and needs emergency care. In adult men, erectile problems were more common than with placebo (about 8% vs 1%). Adult trials also showed urinary hesitation and, less often, urinary retention. Strattera should not be used with narrow-angle glaucoma.

Adderall’s rare warnings run in a different direction: reduced blood flow in fingers and toes (peripheral vasculopathy, including Raynaud’s), serotonin syndrome when combined with certain drugs, and seizures in people prone to them. The Adderall tablets label on DailyMed lists them in full.

Round verdict: Adderall has fewer organ-specific red flags, but both have rare serious risks worth knowing.

Round 8: Coexisting conditions, including Strattera for adults with anxiety

ADHD rarely travels alone. This round looks at three common companions.

• Anxiety: Stimulants can make some anxious people feel jittery. In a 12-week trial of children and teens with ADHD and anxiety, and a 16-week trial of adults with ADHD and social anxiety disorder, atomoxetine did not worsen anxiety. That is why Strattera for adults with anxiety comes up often in clinic visits.
• Tics and Tourette’s: Stimulant labels list new or worsening motor and vocal tics as a possible effect. In an 18-week trial of young patients with ADHD and Tourette’s or chronic tics, atomoxetine did not worsen tics. (Many participants dropped out, mostly because it didn’t help enough.)
• Substance use history: For someone in recovery, or with a household member at risk, a non-controlled drug removes one source of temptation and diversion. Adderall’s label asks prescribers to assess abuse risk before and during treatment. If dependence is a concern, read whether you can become dependent on Adderall.

Round verdict: Strattera, for people with anxiety, tics, or a substance use history.

Final tally

The Adderall vs Strattera score: Strattera takes the misuse, sleep, and coexisting-condition rounds. Adderall takes speed and strength, mood warnings, and the rare-risk round. Appetite and heart effects end in draws. The score shows why the choice depends on the person, not the drug. Other non-stimulant-style options exist too; see how bupropion compares in Adderall vs Wellbutrin.

CYP2D6: why Strattera hits some people harder

Atomoxetine is broken down mainly by a liver enzyme called CYP2D6. People inherit different versions of this enzyme. Most clear the drug fairly quickly, but “poor metabolizers” clear it slowly. According to the label, that applies to about 7% of White people and about 2% of Black and Asian people.

The difference is large. In typical metabolizers, atomoxetine’s half-life is about 5 hours. In poor metabolizers it stretches to about 22 hours, and drug levels build up several times higher. Poor metabolizers in trials had more dry mouth, appetite loss, insomnia, and, in men, erectile problems.

Medicines that block CYP2D6

Some common drugs strongly block the same enzyme and can make anyone act like a poor metabolizer. The label names fluoxetine (Prozac) and paroxetine (Paxil); paroxetine raised atomoxetine exposure about 6.5-fold, and fluoxetine 6- to 8-fold. Quinidine and some other drugs can do this too.

For these patients, the label keeps the same starting and maximum doses but tells prescribers to wait about four weeks before raising the dose, and to raise it only if symptoms haven’t improved and the first dose is well tolerated. That’s one more reason a full, current medication list matters at every visit. It also explains why two people on the same dose can feel very different; the science of why some people need less medication goes deeper.

Adderall interacts differently. Its label warns against MAO inhibitors and lists serotonin syndrome risk with drugs that raise serotonin, and it notes that CYP2D6 inhibitors can raise amphetamine levels as well. Strattera also must not be taken within 14 days of an MAO inhibitor, and oral albuterol can push heart rate and blood pressure higher when combined with it.

Who might be steered toward Strattera

A prescriber weighs many factors in any Adderall vs Strattera decision. These are situations where a non-stimulant ADHD medication like atomoxetine often enters the conversation:

• A past or current substance use disorder, or a household where pills could be taken or sold
• Significant anxiety that worsened on a stimulant
• Tics or Tourette’s syndrome
• Stimulant side effects that couldn’t be managed, such as severe insomnia, appetite loss, or a hard end-of-day crash
• A need for smooth coverage from early morning through bedtime
• A stimulant that simply didn’t help enough after a fair trial
• A preference to avoid controlled-substance refill rules and pharmacy shortages

Who might be steered toward Adderall

• People who need a noticeable effect quickly, such as a student mid-semester
• Those who want flexible dosing, like covering a workday but not a weekend
• People without a substance use history or tic disorder
• Those who had nausea, liver concerns, or mood changes on atomoxetine
• Young children: immediate-release Adderall is labeled for ages 3 and up, while Strattera is approved from age 6
• Patients who also take a strong CYP2D6 blocker and want to avoid a slower atomoxetine schedule

Some people end up on neither. Wake-promoting drugs come up in adult discussions, and Adderall vs Modafinil explains why those aren’t FDA-approved for ADHD. Before any start, the checklist of questions to ask before starting Adderall works well for Strattera too.

Can you take Strattera and Adderall together?

Sometimes, yes, but only under a specialist’s direction. Some psychiatrists add atomoxetine to a stimulant when one drug alone leaves gaps, for example to cover evenings or to allow a lower stimulant dose. This combination is not an FDA-approved pairing, and research on it is more limited than for either drug alone.

The main concern is stacking effects. Each one can push pulse and blood pressure upward, and both can reduce appetite and affect sleep. Prescribers who use the combination typically check vital signs more often and change only one medicine at a time. Combining them is strictly a prescriber’s call, never a home experiment, and never take someone else’s prescription; what happens if someone else takes your prescription explains the risks.

Doctors also look at your full medication record before combining treatments. That is part of why doctors check prescription history, and it protects you from hidden interactions.

Stopping each one

Stopping Strattera

The Strattera label says the drug can be stopped without tapering. In trials, people who stopped showed no symptom rebound and no withdrawal syndrome. ADHD symptoms will gradually return, though, since the drug is no longer working. MedlinePlus still advises talking to your doctor before stopping, so the plan, timing, and next treatment are clear.

Stopping Adderall

Adderall is different. The label describes withdrawal after stopping a stimulant, especially after heavy or long use: low or sad mood, deep tiredness, vivid unpleasant dreams, and sleeping too much or too little. MedlinePlus on dextroamphetamine and amphetamine warns that stopping suddenly after overuse can bring severe depression and exhaustion.

People taking a modest prescribed dose often stop with little trouble, but a prescriber may still suggest a gradual step-down. The guide on how to stop taking Adderall safely covers that process, and Adderall withdrawal symptoms describes what can happen and how to cope.

Switching from one to the other is a common reason for stopping. Because Strattera builds slowly, some prescribers overlap the two briefly rather than leaving a gap. That overlap, if any, is the prescriber’s call. Bring your notes to the next appointment, and use the list of questions to ask at every follow-up visit to keep the switch on track.